Key Highlights
- Psyence Biomedical shares closed up 24% at $4.42.
- The move followed President Trump's commitment to broaden ibogaine research and Right to Try access.
- The University of Miami donated its 1994 ibogaine IND to the federal government.
- The news fueled market interest in psychedelic clinical programs targeting PTSD, alcohol use disorder, and substance use disorder.
Psyence Biomedical Ltd. (NASDAQ: PBM) shares closed up 24% at $4.42 following President Trump's commitment to broaden ibogaine research and Right to Try access.
What Happened
The momentum was sparked by the University of Miami donating its 1994 ibogaine IND to the federal government, fueling market interest in psychedelic clinical programs targeting PTSD, alcohol use disorder, and substance use disorder.
Market Reaction
Shares rose sharply as investors responded to the broader policy signal around ibogaine research, viewing it as a potential tailwind for companies with psychedelic-focused clinical programs, including Psyence Biomedical.
Outlook
Continued developments in federal policy toward ibogaine research and Right to Try access are likely to remain relevant for sentiment toward psychedelic-focused clinical-stage companies like Psyence Biomedical.
FAQs
Q: Why did Psyence Biomedical shares rise 24%?
A: Shares rose after President Trump committed to broaden ibogaine research and Right to Try access, fueling interest in psychedelic clinical programs.
Q: What triggered the renewed attention on ibogaine?
A: The University of Miami's donation of its 1994 ibogaine IND to the federal government.
Q: What conditions do these psychedelic programs target?
A: PTSD, alcohol use disorder, and substance use disorder.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.